3d PRINTING IN MEDICINE
Keeping Up to Date with Developments in the Dynamic Field of 3d Printing, and its Impact on Healthcare
3D Printing in Medicine 2015, 1:1 (27 November 2015)
Personalized medicine and precision medicine are easier to conceptualize than define, and implementation can be even more challenging. 3D printing has intersected medicine to enable both. Personalized medicine is now delivered by “clinical modelers”, impassioned investigators are caretakers who model disease with 3D printing to define pathology, plan intervention, and treat patients.
Creating, manipulating, and printing Standard Tessellation Language (STL) files is challenging; generating a hand-held model from a CT scan is harder than it has to be. Several diagnostic post-processing steps applied to the CT volume (collectively termed “3D visualization”) must be repeated to generate an STL file that is then 3D printed. Multiple software packages are typically required before the STL file is electronically placed on a separate build-tray software platform. In 5 years or less, the inefficiency of medical modeling will be a historical footnote.
Current 3D printing publications are disparate. My group’s summary of the literature (submitted for publication in October 2014) attempted a comprehensive survey of the field stratified by organ section . I personally apologize if your article was not included. However, those papers we did find and include spanned over 50 different journals.
3D Printing in Medicine is designed to provide a common platform peer-review platform. This forum is long overdue. The journal also addressed another missing piece: STL files are invited for submission and can be downloaded for free consumption by our readership. Those engaged in 3D printing are talented, and their creativity should be rewarded with development opportunities. 3D Printing in Medicine invites not only clinical studies, but also “concept papers” that will motivate and connect physicians, industry, engineers, and scientists in general. These papers will benefit from peer review and serve as a platform for funding that will drive further innovations.
The journal will also address the question, “What defines a model that is clinically useful?” There are no 3D printing appropriateness criteria guidelines for a specific clinical scenario. Even the scenarios themselves are yet to be clearly defined. However, the challenge of clinical reimbursement will follow guidelines, and those guidelines in turn must be driven by peer-review studies that show that specific models are not only safe and efficacious, but also that they improve patient outcomes.
3D Printing in Medicine will promote literature standardization. Currently publications incompletely report methodology, limiting reproducibility and careful assessment of appropriateness. The journal will adopt a format for standardized enhance communication. A template format would include the following: printer type, materials, time to print (assuming the object was printed by itself), estimated cost of the materials, and potential overall cost to fabricate the model. Reporting should also include details regarding the print layer thickness and details regarding imaging if the model was created from DICOM images.
Precision remains critical for diagnoses and treatment. An early journal article addresses STL file precision to open a conversation among clinical modelers regarding best practice strategies . Many clinical modelers are our trainees and academic junior staff members who have embraced 3D visualization. I welcome this talented, enthusiastic group to explore 3D Printing in Medicine and translate their inventive spirit to the clinical and scientific communities, and, in the process, make meaningful contributions to improve healthcare.
The author declares that he has no competing interests.
- Mitsouras D, Liacouras P, Imanzadeh A, Giannopoulos AA, Cai T, Kumamaru KK, et al. Medical 3D printing for the radiologist. RadioGraphics. 2015;35. in press..http://www.ncbi.nlm.nih.gov/pubmed/26562233 webcite
- Cai T, Rybicki FJ, Giannopoulos AA, Schultz K, Kumamaru KK, Liacouras P, et al. The residual STL volume as a metric to evaluate accuracy and reproducibility of anatomic models for 3D printing: application in the validation of 3D-printable models of maxillofacial bone from reduced radiation dose CT images. 3D Printing in Medicine. 2015. in press.
Ontology Building for Medical 3D Printing: The Team @ Leaders in Pharmaceutical Business Intelligence (LPBI)
Curator: Aviva Lev-Ari, PhD, RN
Twelve Lecture Series on Medical 3D Printing Applications & Technologies by LPBI’s Medical 3D Printing Team
Curator: Aviva Lev-Ari, PhD, RN
Our PLAN for a US-based ’S’ Corporation
A Global Distributorship of Multivendor Medical 3D Printing Products, Technologies and Services
Leaders in Medical 3D Printing Global Distributorship
M3DP — THREE CORE BUSINESSES are Services of Three Types
1. Global Multi Vendor Distributorship of
- 3D Printing Equipment, and
- Consumable BioInks
2. Consulting Services on Medical Product Concepts and Medical Product Designs using technologies from 1, above
3. R&D — Creation of New Intellectual Property for New Medical Products using 3D Printing, MEMS and Sensors in their Design, Prototyping and Manufacturing
Transaction-based Web Site Design Considerations for M3DP
Curator: Aviva Lev-Ari, PhD RN
NewCo has the following Opening:
- Co-Founder with Aviva — we consider internal candidates
- Members of the Board
- Chairman of the Board
- Introductions to Investors
- Invite to Join as members of the Technical Team: Scientist and Engineers
Proposal for a Matrix Organization – Work-in-Progress
CEO – TBA
CFO – TBA
COO – TBA
Gerard Loiseau, Capital and Venture Financial Backing
Aviva Lev-Ari, PhD, RN – Interim COO
Members of the Technical Team for Regional Business Development
Yoel Ezra, MSc, Medical Devices & Engineering 3D Printing, Israel
Tilda Barliya, PhD, Tissue Engineering, Israel
Danut Dragoi, PhD, Medical 3D Printing, US – West Coast
Irina Robu, PhD, Medical 3D Printing, Canada, US – Mid West
Stephen J Williams, PhD, 3D Printing Pharma, US and Tissue Engineering, US Mid Atlantic
Dr. Justin D Pearlman, MD, PhD, FACC, Product Concepts and Product Design, Cardiovascular and Vascular Applications
The Ontology of Medical 3D Printing Research Category on the PharmaceuticalIntelligence.com Journal is developed and maintained by:
Dr. Pearlman, Aviva and Yoel
- CARDIOVASCULAR & VASCULAR SYSTEMS
Dr. Williams, Dr. Tilda Barliya, Dr. Nelboeck, Dr. Raphael Nir
- Drug Development & Pharma
- Nanotechnology in Drug Delivery
Dr. Irina, Dr. Danut and Gerard (Dental)
- BioMaterials, and any other category
Bill Zurn, Adam, Steven Lerner
- MEMS, Sensors and any other category
BioMedical Technologies FOCUS
NIH and FDA on 3D Printing in Medical Applications: Views for On-demand Drug Printing, in-Situ direct Tissue Repair and Printed Organs for Live Implants
US based ’S’ Corporation – A Global Multivendor Distributorship of Medical 3D Printing:
- 3D Printing for Tissue Engineering — Dr. Irina Robu, Dr. Tilda Barliya, Dr. Danut Dragoi other Team Members
- 3D Printing for Biomedical Applications — Dr. Pearlman, Adam Sonnenberg, Aviva,
- 3D Printing for On Demand Drug Dosing and Drug Printing – Dr. Stephen J Williams, Dr. Peter Nelboeck, Dr. Tilda
- 3D Printing for BioBanking – Dr. Stephen J Williams
- 3D Organ Printing – Dr. Irina Robu
4D BioPrinting: biofabrication of rod-like and tubular tissue engineered constructs using programmable self-folding bioprinted biomaterials
Vladimir Mironov, Visiting Professor, Center for Information Technology Renato Archer, CEO, 3D Bioprinting Solutions
The organ printing technology introduced decade ago is an automated, robotic and computer-aided layer by layer additive biofabrication of functional 3D tissue and organ constructs using living tissue spheroids as building blocks. The organ printing technology consists of three main steps: (i) pre-processing or design of blueprint for bioprinting of human organ; (ii) processing or actual 3D bioprinting using bioink or tissue spheroids, biopaper or bioprintable hydrogel and bioprinter or automatic computer-aided robotic dispenser; and (iii) post-processing or bioreactor-based accelerated tissue maturation. Organ printing is a rapidly emerging technology. The past, present and future of organ printing will be discussed.
- 4D Tissue Engineering – Dr. Irina Robu
ALEXEY BERSENEV on SEPTEMBER 18, 2013 in Tissue Engineering
7. Medical MEMS, Sensors and 3D Printing: Frontier in Process Control of BioMaterials – William Zurn and Steven Lerner
8. BioP3 Technology may be the Future of bioPrinting Human Organs – Dr. Irina Robu
French Hospital Uses Multi-Colored 3D Kidney Prints to Help with Cancer Surgery
9. 3D Printing on Glass for Medical Applications
Intellectual Property of M3DP Team include:
A Team of Technical Experts with advanced degrees in Material Science, BioEngineering and Pharmacology
- Market Intelligence White Paper on 3D Printing Market for Tissue Engineering in US Mid Atlantic by Dr. Stephen J Williams
- Market Intelligence White Paper on 3D Printing Market for Tissue Engineering in US Mid West by Dr. Irina Robu
- Market Intelligence White Paper on 3D Printing Market for Tissue Engineering in Canada by Dr. Irina Robu
- Market Intelligence White Paper on 3D Printing Market for Tissue Engineering in West Coast by Dr. Danut Dragoi (Work-in-Progress)
- Market Intelligence White Paper on 3D Printing Market for Tissue Engineering in Israel by Yoel Ezra, MSc
- Market Intelligence White Paper on 3D Printing Market for Tissue Engineering in Scandinavia by Dr. Yossi Ezer
- Market Intelligence White Paper on 3D Printing Market for Tissue Engineering @P&G by Adam Sonnenberg, Bsc
- Market Intelligence White Paper on 3D Printing Market for Tissue Engineering @GE Life Sciences, @J&J, @MIT – BioMaterials Lab by Aviva
- Market Intelligence White Paper on 3D Printing Market for Tissue Engineering– Global Markets Special Accounts by Gerard Loiseau
- Japan’s Ceramics and Glass Industries: 3D Applications by Dr. Aviva Lev-Ari
11. Medical Devices Industry: Investment Facts and Industry Prospects
12. IP of Dr. Pearlman – Cardiovascular Applications and 3D Printing
13. IP of Dr. Pearlman – Medical Application and 3D Printing
- Translation centers like CIMIT
- 3D Printing start-ups
- Pediatric Cardiac Surgeons – TE Cardiac Devices for Pediatrics (Orphan Devices)
- Big Pharma
- Corporate R&D Departments at Lead Medical Devices Companies:
7A. LIST OF 3D PRINTING STOCKS
BY: JUDD PARKER – INFO@3DPRINTERSTOCKS.COM (Updated: 06/25/2014)
· Arc Group Worldwide (NASDAQ:ARCW)
· Stratasys, Inc. (NASDAQ:SSYS)
· Hewlett-Packard Company (NYSE:HPQ)
· 3D Systems Corp. (NASDAQ:DDD)
· The ExOne Company (NASDAQ:XONE)
· Voxeljet AG (NASDAQ:VJET)
· Group Gorge (NASDAQ:GOE.PA) and (NASDAQ:GGRGF)
· Camtek LTD. (NASDAQ:CAMT)
· Autodesk, Inc. (ADSK)
· Dassault Systemes S.A. (PINK:DASTY)
· Exa Corporation (EXA)
· PTC Inc. (PMTC)
· Cimatron Ltd. (NASDAQ:CIMT)
· Ansys Inc. (NASDAQ:ANSS)
Medical/Biological 3D Printing
· Organovo Holdings, Inc. (ONVO.PK)
3D Scanner Manufacturers
· Faro Technologies Inc. (NASDAQ:FARO)
Top 10 Bioprinters
2. Organovo’s NovoGen MMX (Liver tissue)
3. RegenHU’s 3DDiscovery + Biofactory
4. 3D Bioprinting Solutions’ FABION – Stem cells within hydrogel.
5. Advanced Solutions’ BioAssemblyBot
6. GeSim’s Bioscaffolder 2.1
7. 3Dynamic Systems’ Alpha & Omega
8. Bio3D’s SYN^ and Explorer
9. Aspect Biosystems’ Lab-on-a-printer
10. n3Dbio’s Bioassembler – Printing breast cancer tissue for R&D
Honorable Mention. BioBots BioBot1 – Open source machine
The Top TEN BioPrinters – PRICING DATA
SOURCE & LINK TO VIDEOS
Technology: syringe-based extrusion
Materials: hydrogels, silicone, hydroxipatite, titanium, chitosan
Price: up to $200,000+
2. Organovo’s NovoGen MMX
Technology: syringe based extrusion
Materials: cellular hydrogels
Price: not for sale
3. RegenHU’s 3DDiscovery + Biofactory
Technology: syringe based extrusion
Materials: bioink, osteoink
Price: up to $200,000+
4. 3D Bioprinting Solutions’ FABION
Technology: multiple (photocuring, electromagnetic and extrusion)
Materials: hydrogel, organoids
Price: not for sale
5. Advanced Solutions’ BioAssemblyBot
Technology: six-axes syringe based extrusion
6. GeSim’s Bioscaffolder 2.1
Technology: syringe based extrusion and piezoelectric nanoliter pipetting
Materials: polymers, high viscosity paste materials, alginate, calcium phosphate, silicon, cells and protein solutions
Technology: syringe based extrusion
Materials: bone tissue from PCL, PLA, PGA, PEG, fibrin elastin, collagen, calcium phosphate and hydrogel mixtures
8. Bio3D’s SYN^ and Explorer
Technology: syringe-based extrusion
Materials: polymers, hydrogels
9. Aspect Biosystems’ Lab-on-a-printer
Technology: proprietary (unspecified)
Price: not for sale (partnerships available)
10. n3Dbio’s Bioassembler
Technology: magnetic levitation
Price: $500-750 kits
Honorable Mention. BioBots BioBot1
Technology: syringe-based extrusion, blue light technology
Materials: agarose, collagen, alginate, polyethylene glycol
Other Companies in 3D BioPrinting
- Cyfuse Biomedical : 3D cellular spheroids ; Kenzan method platform
- Rokit: Plan: 3D printing human skin for burn victims.
- TeVido Biodevices : working on printing human nipple tissue for breast reconstructive surgery
- Print alive skin 3D printer which won a recent James Dyson Award, http://www.jamesdysonaward.org/projects/printalive-bioprinter/
- ARC Group Worldwide Announces Acquisition of Kecy…
- Materialise Announces Pricing of Initial Public Offering at…
- Top 10 Industries That Will Be Disrupted By 3D Printing
- Featured: Motif Investing make’s investing in 3d…
7B. Top Ten Cardiovascular Medical Devices Industry Leaders
- Abbott Labs
- Boston Scientific
- St Jude Medical
- Becton Dickson
- Bard (C.R.)
7C. Top Ten Orthopedic Medical Devices Industry Leaders and HealthCare Equipment
- Wright Medical
- ResMed Inc
- Steris Corp
- Sirona Dental Systems
- Varian Medical Systems
- Natus Medical
- Smith & Nephew
Tissue Engineering Start Ups in Israel
Tissue Engineering & Cell Therapy
- BioGenCell Ltd. BioGenCell is a biotechnology company developing medical therapeutic products for a wide range of diseases from adult stem cells extracted…
- BrainStorm Cell Therapeutics BrainStorm is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases…
- Cell Cure Neurosciences Ltd Cell Cure Neurosciences Ltd. (Cell Cure) is focused on the development of cell therapies for retinal and neural degenerative diseases. Its therapeutic…
- CollPlant Ltd. CollPlant is a medical device company focused on advancing regenerative medicine by utilizing its proprietary processing technologies for…
- Gamida Cell Ltd. Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative…
- Kadimastem Ltd. Kadimastem is a biotechnology company focused on the industrial development and commercialization of human embryonic stem cell (hESC)-based products….
- MacroCure Ltd. Macrocure Ltd. is a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal…
- MGVS Ltd. MGVS develops unique products for very large patient populations who cannot be treated adequately with current therapeutic modalities, with a…
- Orgenesis A development stage private Israeli company owned by USA public company ORGS:OTCBB). Orgenesis aimed to cure dibetes by receiving liver biopsy…
- Pluristem Therapeutics Inc. Pluristem Therapeutics Inc. is a clinical-stage biotechnology company using placental cells and a unique, proprietary, three-dimensional (3D)…
- Beauty-Cell Ltd. Collection, processing and storage of mesenchymal stem cells from fat.
- Carticure Ltd. Carticure Ltd. develops a novel treatment for cartilage repair. Our product, Cartimove is a 100% hyaline cartilage membrane produced from neonatal…
- Core Dynamics Core Dynamics is developing new methods for freezing, thawing and freeze-drying cells and tissues. The company’s unique freezing and thawing…
- V.S. Engineering Ltd. D.V.S. Engineering, Ltd. is a cutting-edgw developer and producer of medical devices and accessories. We are presently engaged in developing…
- Enlivex Therapeutics Ltd Enlivex is an Israeli-based cell immunotherapy company established in October 2005 by Dr. Dror Mevorach, a world-renowned expert on cell apoptosis. Enlivex…
- Life Bank – BioCord Ltd. Cord Blood Banking.
- Medgenics Ltd BIOGENICS LTD. is a wholly owned Israeli subsidiary of Medgenics. The company is developing a new, cost effective, long term and patient…
- NVR Research Ltd. NVR (Nerve and Vascular Reconstruction) Research Ltd is a small Israeli company established with the aim to develop composite implants for two…
- Regentis Biomaterials Ltd. Regentis Biomaterials is a tissue repair company that is developing and commercializing innovative biodegradable…
- Rejuvenation Ltd. Biological Rejuvenation is developing a new method for the biological rejuvenation by a new collagenolytic agent. This agent leads to stimulation…
- Sheltagen Medical Ltd The company develops human bone tissue for implantation in patients with fractures in their bones, bone deficiencies from various reasons or…
- SOURCES on 3D Printing for Medical Applications
3D-Printing in the Life Sciences Conference, July 8-9, 2015, Boston, MA – Organ-on-a-Chip World Congress
- Medical Devices Industry: Investment Facts & Industry Prospects
Curators: Stephen J Williams, PhD, Adam Sonnenberg, BSc and Aviva Lev-Ari, PhD, RN
- Oxford Performance Materials gets FDA nod for 3-D printed spinal implant
- Tissue Engineered Medical Products
Workshop-Handout-Tissue-Engineered-Medical-Products – Lack E. Lemons, PhD
3D Printing Applications to Cardiovascular Diseases
- Hybrid Imaging 3D Model of a Human Heart by Cardiac Imaging Techniques: CT and Echocardiography
- 3D printing from MRI untangles congenital heart surgery, November 21, 2014
- Dassault unveils 3D virtual heart model, May 20, 2014
- Researchers launch library of 3D heart models, April 18, 2013
- Giant virtual reality chamber boosts 3D echo accuracy, August 2, 2007
3D Printing in Medicine 2015, 1:3 (27 November 2015)
- Comparison of a Closed System to a Standard Open Technique for Preparing Tissue-Engineered Vascular Grafts
- Multiple Complex Coronary Plaques in Patients with Acute Myocardial Infarction
- Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells
- Evaluation of remodeling process in small-diameter cell-free tissue-engineered arterial graft
Cell Therapy Manufacturing and Gene Therapy Conference, December 2-3, 2015, Sheraton Airpost Hotel, Brussels, Belgium
3D PRINTING — LEADERS in ACADEMIA
Joachim Kohn is a leader in biomaterials science and widely known for the development of tyrosine-derived, resorbable polymers, one of which is now used in an FDA-approved medical device. Kohn’s current research efforts focus on the development of a new “discovery paradigm” for revolutionary biomaterials using combinatorial and computational methods to optimize the composition and properties of biomaterials for specific applications, particularly tissue engineering and drug delivery. As a first demonstration of the utility of this approach, Kohn led a team of scientists who discovered an optimized polymer for use in a fully degradable cardiovascular stent which has been tested in clinical trials in Germany and Brazil. Additional clinical trials are planned. Kohn’s combinatorial biomaterials design approach was also used for the development of optimized polymers by Lux Biosciences (ophthalmic applications) and by Trident Biomedical (orthopedic applications).
Yi Arnold, PhD, is currently a senior scientist at Osiris Therapeutics, Inc. She obtained her PhD in Biomedical Engineering from City College of New York and followed by a postdoctoral training at Yale Medical School. After that, she joined the Laboratory for Stem Cells and Tissue Engineering at Columbia University and performed research on cardiac tissue engineering. Before joining Osiris, she worked as a senior scientist at Kinetic Concepts, Inc.
Matthew Becker is a Professor in the Departments of Polymer Science and Biomedical Engineering at The University of Akron. His research group focuses on synthesizing highly functional macromolecular materials for medical device and regenerative medicine applications. He is the Director the industrially-focused Akron Functional Materials Center and also leads the Biomaterials efforts of the Austen Bioinnovation Institute in Akron. Prior to joining UA, Dr. Becker was a project leader and NRC postdoctoral fellow in the Polymers Division of the National Institute of Standards and Technology (NIST). He also led the biomaterials efforts of NIST Combinatorial Methods Center and facilitated Polymers Division interactions with the research divisions of the U.S. FDA. Dr. Becker received his PhD in Organic Chemistry in 2003 from Washington University in St. Louis under the supervision of Professor Karen L. Wooley where he was an NIH Chemistry-Biology Interface Training Fellow. He received his BS in Chemistry in 1998 from Northwest Missouri State University.
Scott P. Bruder, MD, PhD, is an insightful and energetic healthcare leader with a 20-plus year history of bridging basic science, clinical medicine, and industrial development expertise to deliver innovative, commercially successful products that improve patients’ lives around the world. Experience in medical devices, diagnostics, biotechnology, and life science research tools fortify an expansive analytical skill set for this resilient, poised and influential C-Suite executive. An award-winning scientist and clinician, equally comfortable in the laboratory, at the lectern, in the Boardroom or on Capitol Hill, he delivers impactful results by inspiring multi-disciplinary teams to be collaborative, rigorous and decisive. This seasoned Senior Executive, University Professor, and FDA Advisory Committee Member provides a unique bench-to-bedside perspective on unmet needs, development strategy and the path to commercialization. An avid long-distance runner, jazz pianist, devoted husband and dedicated father, his core beliefs are based on the principles of passion, commitment and discipline.
Christopher S. Chen is a Professor of Biomedical Engineering at Boston University and the Harvard Wyss Institute for Biologically Inspired Engineering, has been instrumental in developing engineered cellular microenvironments to understand how cells build tissues. He serves as a fellow for the American Institute for Medical and Biological Engineering, member of the Faculty of 1000, Editorial Board for Science Translational Medicine, Annuals Reviews of Cell and Developmental Biology, and Developmental Cell. He received his Ph.D. from M.I.T., and M.D. from Harvard Medical School. He was founding director of the Penn Center for Engineering Cells and Regeneration before his current appointment.
Marcus Cicerone is a Project Leader in the Polymers Division of the National Institute of Standards and Technology. He received his Ph.D. in Physical Chemistry at the University of Wisconson-Madison. Over the past 9 years he has led a team of NIST staff and postdocs to many pioneering accomplishments that have laid the foundation for high-speed spectroscopic imaging using broadband coherent Raman scattering. In 2004, his was the first group to demonstrate broadband coherent anti-Stokes Raman scattering (BCARS) microscopy. Since then, he has introduced numerous hardware and software improvements to the methodology. Among these, his group has engineered continuum laser pulses that were far superior for BCARS to those previously available and also devised a pulse-shaping approach that allowed us to obtain background-free (pure Raman) signal. He later invented a mathematical approach based on a Kramers-Kronig transform for retrieving the pure Raman spectrum directly from the raw CARS signal, making his the first group to obtain quantitative vibrational fingerprint spectra using coherent Raman methods in biological tissues or cells, and showing that BCARS was then 50-fold faster than spontaneous Raman imaging. During the same period Dr. Cicerone has directed a multi-PI R01 grant for stabilizing proteins in biopharmaceutical and drug delivery applications.
Kacy Cullen is an Assistant Professor of Neurosurgery at the University of Pennsylvania and the Philadelphia VA Medical Center (http://www.med.upenn.edu/cullenlab/). He received a Ph.D. in Biomedical Engineering from the Georgia Institute of Technology in 2005, followed by postdoctoral fellowships in Neuroengineering at Georgia Tech and at the Center for Brain Injury & Repair at Penn. Dr. Cullen’s research program operates at the intersection of Neural Engineering and Neurotrauma. He is a leader in neural tissue engineering repair strategies, having pioneered novel “living scaffolds” for neuroregeneration, micro-tissue engineering to restore brain circuitry and biohybrid neuroprosthetic interfaces.
Mark A. Davies received his B.A. in Chemistry from New York University. His Ph.D. thesis project topic was Raman Optical Activity, directed by Prof. Max Diem at the City University of New York. There followed postdoctoral work on infrared spectroscopic studies of acyl chain conformational disorder in lipids with Prof. Richard Mendelsohn at Rutgers University, work which was continued as a Research Assistant Professor in the Biochemistry Department at Georgetown University School of Medicine. Since then, Dr. Davies has concentrated on in vivo measurement of the efficacy of skin care products and cosmetics at Unilever, L’Oreal, and, presently, at Ashland Specialty Ingredients.
Michael A. Davitz is both a physician-scientist and attorney. His practice focuses on creating value for clients through the development and effective enforcement of intellectual property rights. He is a registered U.S. patent attorney as well as a physician with over 15 years of experience in biomedical research, and more than 18 years of experience providing strategic counseling to clients in all aspects of intellectual property law. Michael received his J.D. from New York University in 1997, his M.D. from the College of Physicians and Surgeons at Columbia University in 1983, and his B.A. from Yale University in 1978. Prior to law school, he was an assistant professor of pathology and environmental medicine at New York University School of Medicine, where he was a Lucille P. Markey Scholar in the Biomedical Sciences. Following law school, he practiced law at the firms of Darby & Darby and White & Case. He then moved in-house as head of intellectual property for Taro Pharmaceuticals, a multinational pharmaceutical company. After Taro, he became a partner at Axinn Veltrop & Harkrider LLP in the biomedical group. He has published over 25 papers in peer-reviewed scientific journals such as Science and Nature. He is a regularly invited speaker on Hatch-Waxman and other patent issues with the American Conference Institute, Practicing Law Institute, IQPC and the Commercial Law Development Program of the U.S. Department of Commerce. He is conversant in Russian.
Murat Guvendiren received his Ph.D. in Materials Science and Engineering from Northwestern University with a minor in Bioengineering. He was a postdoc in Materials Science and Engineering and Bioengineering Departments at the University of Pennsylvania. He joined Rutgers as an Assistant Research Faculty at the New Jersey Center for Biomaterials. His research interests include development of hydrogels and polymeric biomaterials, biomimetic material design, surface patterning, cell-biomaterial interactions; in particular cellular interactions with dynamic and patterned materials. His current research focuses on applications of 3D printing technologies to biomaterials and medical devices, including design of novel ink formulations. The applications of his research range from fundamental understanding of stem cell behavior using materials-based approaches to fabricating intelligent scaffolds for regenerative medicine.
Frederick Halperin is Senior Scientist, Radiation Sterilization at J&J Sterility Assurance in Raritan, NJ, and is responsible for electron beam and gamma radiation processing, including sterilization dose setting, dose mapping, dosimetry systems, and maximum dose studies. He is the Particle Accelerator Safety Officer and assistant Radiation Safety Officer. Fred has contributed to publications on electron beam and gamma irradiation of polymers and pharmaceuticals. He is a member of the ASTM International Committee E61 on Radiation Processing, and is Co‐Chair of the Balloting Task Group.
Scott Hanton is the General Manager for Intertek Allentown. Prior to his current role, he was the Laboratory Operations Manager and Chief Scientist in Allentown. He joined the Intertek network in 2010 as part of the outsourcing deal with Air Products & Chemicals. He earned a BS in Chemistry from Michigan State University and a PhD in Physical Chemistry from the University of Wisconsin-Madison. Scott has been active in polymer mass spectrometry and laboratory management.
Hilton Kaplan is a Plastic, Reconstructive and Maxillofacial Surgeon, and a Biomedical Engineer. His research focuses on neurosciences (neural prosthetics and implantable man-machine interfaces), and tissue engineering (decellularized composite tissues for limb and face allotransplantation). Dr. Kaplan is Associate Director of the NJ Center for Biomaterials and a Research Associate Professor at Rutgers University; and an Adjunct Professor in Regulatory Science at the University of Southern California. Dr. Kaplan has held various clinical and research positions in industry, including Senior Medical Director at Allergan (Fortune 500 healthcare) and Vice President of Clinical Sciences at LifeCell (pioneered decellularizing dermis). He has a long history of passionately advocating for burn prevention and reconstruction (as a burn surgeon, a founding board member of the non-profit Grossman Burn Foundation, and the adoptive father of a spirited burn survivor), and for craniofacial reconstruction (as a founding director of the non-profit Look-at-Us Alliance for Craniofacial Differences).
Robert A. Latour obtained his Ph.D. in Bioengineering with an emphasis on biomaterials from the University of Pennsylvania in 1989. He then accepted a faculty position in the Department of Bioengineering at Clemson University, where he presently serves as the McQueen-Quattlebaum Professor of Bioengineering. Prof. Latour’s research focuses on the study of interactions between proteins and surfaces, with a specific focus on the development of molecular modeling and simulation methods to predict, visualize, and understand these interactions at the molecular level. He has published over a 100 book chapters and journal articles in the field of biomaterials.
Prabhas Moghe is a Distinguished Professor of Biomedical Engineering of Chemical and Biochemical Engineering at Rutgers University. Dr. Moghe received his Ph.D. in Chemical Engineering from the University of Minnesota in 1993, and trained on a postdoctoral fellowship in Bioengineering at Harvard Medical School from 1993 to 1995. He joined the Rutgers faculty in 1995 where he has held several research leadership roles including Vice-Chair of Biomedical Engineering, PI and Director on the NSF-sponsored IGERT program at Rutgers on Integratively Engineered Biointerfaces (2003-) and Integrated Science & Engineering of Stem Cells (2008-13); PI/Director of a Nanoscale Interdisciplinary Research Team (NIRT) (2006-2012); Director of Rutgers-UMDNJ Joint Graduate Program in Biomedical Engineering (2007-2010); CORE PI for NIH-sponsored Integrated Research Center on Polymeric Biomaterials (2003-2018); and School of Engineering Diversity Champion for the NE-AGEP (2005-). He was appointed as graduate faculty member of the Graduate Program in Cell and Developmental Biology (Molecular Biosciences) at Rutgers in 1998. Since 2008, Dr. Moghe has been Adjunct Professor of Surgery, Division of Bioengineering, Robert Wood Johnson Medical School.
Dipanjan Nag is the CEO and President of IP Shakti LLC, a pre-eminent patent advisory and commercialization advisory service. He was previously the Executive Director, Office of Technology Commercialization at Rutgers University. Dr. Dipanjan Nag was a Vice President at ICAP Ocean Tomo an intellectual property transaction firm, a subsidiary of ICAP Plc. He concentrated on private sale of biotechnology and life sciences technology areas at ICAP Ocean Tomo. Before that he was a Director at Ocean Tomo, an intellectual property merchant banc, responsible for private sale, patent auctions and valuation of intellectual property assets. Dipanjan also brings with him a wealth of academic technology transfer experience. He was the Director of Operations in the Office of Technology Development at the University of Nebraska-Lincoln (UNL) prior to joining Ocean Tomo. Dipanjan was responsible for successfully licensing numerous technologies and several spin out companies from the University including the major licensing deal with The Monsanto Company for a biotechnology invention.
Judith E. O’Grady is the Corporate Vice President of Global Regulatory Affairs for Integra LifeSciences Corporation. Ms. O’Grady has worked in the areas of medical devices and collagen technology for over 30 years. During her career she has held positions with Colla-Tec, Inc. a Marion Merrell Dow Company, Surgikos, a Johnson & Johnson company, and was on the faculty of Boston University College of Nursing and Medical School. Ms. O’Grady led the team that obtained approval from the Food and Drug Administration (FDA) for INTEGRA® Dermal Regeneration Template, the first skin regenerative product approved by the FDA, DuraGen® Dural Graft Matrix, DuraGen Plus® Dural Regeneration Matrices, and NeuraGen® Nerve Guide, as well as over 500 FDA and international submissions and approvals. She has been an integral part of the regulatory due diligence process on many of Integra’s acquisitions, is a published author, and is listed on the patent for the DuraGen® Dural Graft Matrix . Ms. O’Grady has presented both nationally and internationally on regulatory and compliance issues. She received her B.S. degree from Marquette University and M.S.N. in Nursing from Boston University and has Regulatory Affairs Certification.
Jean E. Schwarzbauer, Ph.D is Professor and Associate Chair of Molecular Biology at Princeton University. She received her Ph.D. from the University of Wisconsin and was a post-doctoral fellow at MIT before joining the Princeton University faculty. She has a long record of service including ASMB President, ASCB Secretary, editor of major cell biology journals, and membership on many advisory boards and grant review panels. Dr. Schwarzbauer has organized conferences in cell and matrix biology and bioengineering. At Princeton, she teaches cell biology and conducts NIH-funded research in tissue repair and regeneration, cancer, and stem cell biology.
Cathryn Sundback , Sc.D. is an Assistant Professor at Harvard Medical School, Director of the Laboratory for Tissue Engineering and Organ Fabrication at the Massachusetts General Hospital, and the Director of the Biomaterials Core within the Center for Regenerative Medicine at the Massachusetts General Hospital. A biomaterialist by training, Dr. Sundback has considerable expertise in the biocompatibility of synthetic and natural biomaterials. Her research focuses on the application of these biomaterials for tissue engineering of facial and limb tissues, particularly peripheral nerve, skeletal muscle, cartilage, and bone. She is currently developing engineered skeletal muscle and cartilage tissues as clinically translatable models and as in vitro models for drug discovery.
Dr. William J. (Bill) Welsh holds the Norman H. Edelman Endowed Professorship in Bioinformatics in the Department of Pharmacology at the Robert Wood Johnson Medical School (RWJMS), Rutgers University in Piscataway NJ. Concurrently, he serves as Director of the Division of Cheminformatics in the Biomedical Informatics Shared Resource at the Rutgers-Cancer Institute of New Jersey (R-CINJ). Previously Dr. Welsh was the Founding Director and Principal Investigator of the EPA-supported Environmental Bioinformatics and Computational Toxicology Center. He also previously served as Founding Director and Principal Investigator of the Informatics Institute at the University of Medicine & Dentistry of New Jersey (UMDNJ, now Rutgers). He is a member of various centers and institutes of excellence at Rutgers University, including the Cancer Institute of New Jersey, the New Jersey Center for Biomaterials, the College of Pharmacy, and the Environmental & Occupational Health Sciences Institute (EOHSI).
Pamela C. Yelick, Ph.D. is a tenured Full Professor in the Department of Orthodontics, and Director of the Division of Craniofacial and Molecular Genetics at Tufts University. Yelick Lab grant support from NIH/NIDCR, NIH/NIAMS, AFIRM/DoD and Osteo Sciences Foundation is being used to study mineralized tissue development, disease and regeneration. Dr. Yelick is internationally recognized as a leader in dental tissue engineering and craniofacial development. Current efforts to bioengineer coordinated bone and tooth constructs are anticipated to result in improved methods for functional craniofacial reconstructions.